---
title: "Profusa Updates Financing Terms: Note Now Convertible; 19.99% Cap Added; Warrant Amended"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284648883.md"
description: "Profusa has updated its financing terms to enhance flexibility and comply with Nasdaq rules. The company modified its promissory note with NorthView Sponsor I, maintaining $1.87M outstanding, removing interest, and extending maturity to Dec 31, 2026, with an equity conversion at 95% of the closing price or $0.35 per share, subject to a 19.99% cap. Additionally, Profusa amended a warrant with Ascent Partners Fund to remove automatic conversion provisions. Shareholder approval will be sought within 90 days for the exchange cap."
datetime: "2026-04-29T21:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284648883.md)
  - [en](https://longbridge.com/en/news/284648883.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284648883.md)
---

# Profusa Updates Financing Terms: Note Now Convertible; 19.99% Cap Added; Warrant Amended

Profusa updated multiple financing instruments to enhance flexibility and align with Nasdaq rules. The company modified its promissory note with NorthView Sponsor I, keeping $1,869,796 outstanding, removing interest, extending maturity to Dec 31, 2026, and adding an equity conversion at the greater of 95% of the closing price or $0.35 per share, subject to a 4.99% cap. A subsequent amendment added a 19.99% exchange cap unless shareholder approval is obtained, with a commitment to seek such approval within 90 days and periodically thereafter. Separately, Profusa amended a warrant with Ascent Partners Fund to remove automatic conversion or assumption provisions in fundamental transactions, with all other warrant terms unchanged.

**Agreement 1: Profusa Amends Note; $1.87M Outstanding, Convertible at 95% of Price or $0.35 Floor**

-   **Agreement type**: Note Modification and Conversion Agreement
-   **Counterparty**: NorthView Sponsor I
-   **Signed / Effective**: Apr 24 2026 / same
-   **Duration / Termination**: Until Dec 31 2026
-   **Reason**: Extend maturity and enable equity conversion flexibility

**Agreement 2: Profusa Adds 19.99% Exchange Cap, Will Seek Shareholder Approval Under Nasdaq Rules**

-   **Agreement type**: Amendment No. 1 to Note Modification and Conversion Agreement
-   **Counterparty**: NorthView Sponsor I
-   **Signed / Effective**: Apr 29 2026 / same
-   **Duration / Termination**: At will
-   **Reason**: Comply with Nasdaq shareholder approval requirements

**Agreement 3: Profusa Amends April 2026 Warrant, Removes Fundamental Transaction Conversion Terms**

-   **Agreement type**: Amendment to Warrant to Purchase Shares of Common Stock
-   **Counterparty**: Ascent Partners Fund
-   **Signed / Effective**: Apr 29 2026 / same
-   **Duration / Termination**: At will
-   **Reason**: Adjust warrant terms for potential transactions

Original SEC Filing: Profusa, Inc. \[ PFSA \] - 8-K - Apr. 29, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PFSA.US](https://longbridge.com/en/quote/PFSA.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [NVACW.US](https://longbridge.com/en/quote/NVACW.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)